title: Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
abstract: Despite the availability of various anticancer agents, Multiple Myeloma (MM) remains incurable in most cases, along with high relapse rate in the patients treated with these agents. The year 2015 saw major advancements in our battle against multiple myeloma. In 2015, the U.S. Food and Drug Administration (FDA) approved three new therapies for multiple myeloma, namely Ixazomib (an oral proteasome inhibitor), Daratumumab and Elotuzumab (monoclonal antibodies against CD38 and SLAMF7 respectively). The purpose of this review is to provide a detailed analysis of these aforementioned breakthrough therapies and two other newer agents, Filanesib (kinesis spindle inhibitor) and selinexor (SINE inhibitor), presented at the 2015 annual meeting of American Society of Hematology (ASH). We also describe the role of agents targeting PD-1 axis and chimeric antigen receptor T (CAR-T) cells in the treatment of MM.
authors.affiliation: Department of Hematology, Zhongshan Hospital, Xiamen University, Fujian Medical University Clinic Teaching Hospital, Xiamen, China.
authors.forename: Kejie
authors.initials: K
authors.lastname: Zhang
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.|University of Texas Health Science Center, Houston, Texas, USA.
authors.forename: Aakash
authors.initials: A
authors.lastname: Desai
authors.affiliation: Department of Hematology, Xinqiao hospital, Third Military Medical University, Chongqing, China.
authors.forename: Dongfeng
authors.initials: D
authors.lastname: Zeng
authors.affiliation: Institute of Hematology and Oncology, Harbin first Hospital, Harbin, China.
authors.forename: Tiejun
authors.initials: T
authors.lastname: Gong
authors.affiliation: Department of Hematology, Hebei Yanda Ludaopei Hospital, Beijing, China.
authors.forename: Peihua
authors.initials: P
authors.lastname: Lu
authors.affiliation: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000627:therapeutic use*; D001896:Boron Compounds / Q000009:adverse effects / Q000627:therapeutic use; D003226:Congresses as Topic; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D006834:Hydrazines / Q000009:adverse effects / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D061988:Proteasome Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D013830:Thiadiazoles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; D001896:Boron Compounds; D006834:Hydrazines; D061988:Proteasome Inhibitors; D047428:Protein Kinase Inhibitors; D013830:Thiadiazoles; D014230:Triazoles; C546027:elotuzumab; C585161:selinexor; C556306:daratumumab; C548400:ixazomib; C544550:filanesib; D005998:Glycine
keywords: Ixazomib; daratumumab; elotuzumab; multiple myeloma